---
title: "Capricor says deramiocel meets primary endpoint in HOPE-3 Phase 3 Duchenne muscular dystrophy trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290970130.md"
description: "Capricor Therapeutics announced that its drug candidate deramiocel met the primary endpoint in the Phase 3 HOPE-3 trial for Duchenne muscular dystrophy. Five-year open-label extension results showed sustained slowing of functional decline and stable heart function, indicating durable benefits. Safety profiles remained consistent with no new signals. The company's Biologics License Application (BLA) is under FDA review, with a PDUFA target action date set for August 22, 2026."
datetime: "2026-06-26T13:05:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290970130.md)
  - [en](https://longbridge.com/en/news/290970130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290970130.md)
---

# Capricor says deramiocel meets primary endpoint in HOPE-3 Phase 3 Duchenne muscular dystrophy trial

-   Capricor flagged new five-year open-label extension results for deramiocel in Duchenne muscular dystrophy, set for presentation June 27 at PPMD 2026. \* The update showed sustained slowing of functional decline with stable heart function over the follow-up, supporting a durable benefit profile. \* Previously reported HOPE-3 Phase 3 results will also be presented June 26, with the trial meeting its main functional endpoint and a key cardiac endpoint. \* Safety remained consistent across studies, with no new safety signals reported. \* The readouts come with deramiocel’s BLA under FDA review ahead of an Aug. 22, 2026, PDUFA target action date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606260905PRIMZONEFULLFEED9753077) on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)

## Related News & Research

- [Capricor publishes advisory committee presentation on deramiocel clinical data in Duchenne muscular dystrophy](https://longbridge.com/en/news/293953736.md)
- [Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel | CAPR Stock News](https://longbridge.com/en/news/293951290.md)
- [Capricor disputes FDA post-hoc analyses of deramiocel data ahead of July 29 advisory panel](https://longbridge.com/en/news/293950459.md)
- [QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli](https://longbridge.com/en/news/293956617.md)
- [Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel](https://longbridge.com/en/news/293853158.md)